Literature DB >> 21843732

Medical management of motility disorders in patients with intestinal failure: a focus on necrotizing enterocolitis, gastroschisis, and intestinal atresia.

Bryan J Dicken1, Consolato Sergi, Frederick J Rescorla, Francine Breckler, David Sigalet.   

Abstract

BACKGROUND: Intestinal failure (IF) is the dependence upon parenteral nutrition to maintain minimal energy requirements for growth and development. It may occur secondary to a loss of bowel length, disorders of motility, or both. Short bowel syndrome (SBS) is a malabsorptive state resulting from surgical resection, congenital defect, or diseases associated with loss of absorptive surface area. A particularly vexing problem is associated with whole bowel and/or segmental intestinal dysmotility. Motility disorders within the context of SBS and IF may relate to rapid intestinal transit secondary to loss of intestinal length, dysmotility associated with loss or poor antegrade peristalsis, or gastroparesis. Therapy may be classified into medical (prokinetic and antidiarrheal agents) and surgical to deal with the overdistended poorly motile bowel.
METHODS: We performed a systematic review of the literature pertaining to IF, SBS, and dysmotility in the pediatric population with gastroschisis, necrotizing enterocolitis, and intestinal atresia. In addition to the available treatment options, we have provided a review of the literature and a summary of the available evidence.
CONCLUSION: Despite relatively poor level of evidence regarding the application of promotility and antidiarrheal medications in patients with SBS and IF, these agents continue to be used. Herein, we provide a review of the physiology and pathophysiology of intestinal motility/dysmotility and available strategies for the use of promotility and antidiarrheal agents in patients with IF/SBS.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21843732     DOI: 10.1016/j.jpedsurg.2011.04.002

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  19 in total

1.  The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats.

Authors:  Evelyn Jantscher-Krenn; Monica Zherebtsov; Caroline Nissan; Kerstin Goth; Yigit S Guner; Natasha Naidu; Biswa Choudhury; Anatoly V Grishin; Henri R Ford; Lars Bode
Journal:  Gut       Date:  2011-12-03       Impact factor: 23.059

Review 2.  Nutritional support of infants with intestinal failure: something more than fishy is going on here!

Authors:  David Sigalet; Viona Lam; Dana Boctor; Mary Brindle
Journal:  Pediatr Surg Int       Date:  2013-10       Impact factor: 1.827

Review 3.  Short bowel syndrome in the NICU.

Authors:  Sachin C Amin; Cleo Pappas; Hari Iyengar; Akhil Maheshwari
Journal:  Clin Perinatol       Date:  2013-01-17       Impact factor: 3.430

Review 4.  Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.

Authors:  Per T Sangild; Denise M Ney; David L Sigalet; Andreas Vegge; Douglas Burrin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-10-23       Impact factor: 4.052

5.  Enzymatic and Chemoenzymatic Syntheses of Disialyl Glycans and Their Necrotizing Enterocolitis Preventing Effects.

Authors:  Hai Yu; Xuebin Yan; Chloe A Autran; Yanhong Li; Sabrina Etzold; Joanna Latasiewicz; Bianca M Robertson; Jiaming Li; Lars Bode; Xi Chen
Journal:  J Org Chem       Date:  2017-11-22       Impact factor: 4.354

Review 6.  Improved enteral tolerance following step procedure: systematic literature review and meta-analysis.

Authors:  Melissa A Fernandes; Danielle Usatin; Isabel E Allen; Sue Rhee; Lan Vu
Journal:  Pediatr Surg Int       Date:  2016-07-26       Impact factor: 1.827

7.  Clinical problem-solving: Short bowel syndrome in an infant.

Authors:  Claude C Roy; Véronique Groleau; Mona Beaunoyer; Valérie Marchand
Journal:  Paediatr Child Health       Date:  2013-08       Impact factor: 2.253

Review 8.  Fish oil-based lipid emulsions in the treatment of parenteral nutrition-associated liver disease: an ongoing positive experience.

Authors:  Muralidhar H Premkumar; Beth A Carter; Keli M Hawthorne; Kristi King; Steven A Abrams
Journal:  Adv Nutr       Date:  2014-01-01       Impact factor: 8.701

Review 9.  Hirschsprung's disease: clinical dysmorphology, genes, micro-RNAs, and future perspectives.

Authors:  Consolato Maria Sergi; Oana Caluseriu; Hunter McColl; David D Eisenstat
Journal:  Pediatr Res       Date:  2016-09-28       Impact factor: 3.756

10.  Intestinal dysmotility after bowel resection in rats is associated with decreased ghrelin and vimentin expression and loss of intestinal cells of Cajal.

Authors:  Igor Sukhotnik; Yoav Ben-Shahar; Yulia Pollak; Shlomi Cohen; Hadar Moran-Lev; Tal Koppelmann; Migel Gorenberg
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-12-16       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.